English | Español
Patient Daily | Mar 18, 2026

Experimental hookworm vaccine shows promising protection in phase 2 human trial
Patient Daily | Mar 18, 2026

American Tort Reform Association releases report on scientific claims in mass tort litigation
Patient Daily | Mar 17, 2026

FDA move to single pivotal study raises standards for drug applications
Patient Daily | Mar 17, 2026

Novo Holdings’ assets fell 34% in 2025 as Novo Nordisk struggled
Patient Daily | Mar 17, 2026

J&J and AbbVie CEOs receive pay increases exceeding $30 million in 2025
Patient Daily | Mar 17, 2026

BridgeBio reports positive Phase 3 results for limb-girdle muscular dystrophy drug
Patient Daily | Mar 17, 2026

Eli Lilly warns of safety risks in compounded tirzepatide formulations
Patient Daily | Mar 17, 2026

Biogen, Sarepta, and Edgewise present new data at Muscular Dystrophy Association 2026 conference

Trending
+ Regulatory
Patient Daily | Apr 28, 2026

Archo Advocacy CEO Toresco on PBMs: 'PBMs profit from keeping prices high. Patients pay the spread'
+ Pharmaceuticals
Patient Daily | Apr 24, 2026

Washington Post Opinion Editor on 340B drug discounts: 'The program has become a profit-making venture for big businesses'
+ Regulatory
Patient Daily | Apr 29, 2026

USC Schaeffer Center's Sood on PBMs: 'If PBMs want to claim they save employers and patients billions, they should be willing to prove it'
+ Regulatory
Patient Daily | Apr 24, 2026

Steve Forbes on 340B program: Hospitals use it ‘to divert taxpayer-subsidized benefits for patients to unrelated interests’